Aspirin Versus Clopidogrel in Chronic Coronary Syndrome in Arabian Gulf Countries
ARCTURUS
Aspirin Versus Clopidogrel for Secondary Prevention of Atherosclerotic Cardiovascular Events in Patients With Chronic Coronary Syndrome in the Arabian Gulf Countries: A Randomized, Open-label, Multi-Center Trial by the Gulf Trialists' Collaboration
interventional
6,740
0 countries
N/A
Brief Summary
Determine the long-term efficacy of clopidogrel compared with aspirin in reducing heart or brain attacks in patients with stable heart disease
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for phase_3
Started Apr 2027
Longer than P75 for phase_3
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
April 28, 2026
CompletedFirst Posted
Study publicly available on registry
May 7, 2026
CompletedStudy Start
First participant enrolled
April 1, 2027
ExpectedPrimary Completion
Last participant's last visit for primary outcome
April 1, 2032
Study Completion
Last participant's last visit for all outcomes
April 1, 2032
May 7, 2026
May 1, 2026
5 years
April 28, 2026
May 4, 2026
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Four-point MACCE, defined as a composite of Cardiovascular Death, Non-fatal Myocardial Infarction, Non-fatal Ischemic Stroke, and Ischemia-driven Revascularization.
Clinical follow-up by out-patient clinic visits or phone calls
3 years
Study Arms (2)
Aspirin
ACTIVE COMPARATORAspirin
Clopidogrel
ACTIVE COMPARATORClopidogrel
Interventions
Eligibility Criteria
You may qualify if:
- Age ≥18 years.
- Significant coronary artery disease (coronary angiogram documentation of Left Main artery lesion ≥50% and/or lesion(s) ≥70% in other coronary arteries, and/or FFR\<0.8 or iFR\<0.9).
- Completed at least 6 months post ACS (regardless of the bleeding risk, anti-platelet strategy, revascularization strategy "PCI, CABG, or conservative medical management only", before randomization).
- Agreement to give written informed consent.
You may not qualify if:
- History of hypersensitivity to aspirin or clopidogrel.
- Presence of non-cardiac comorbidity with life expectancy ≤2 years from randomization.
- Plan for surgery or intervention which requires stopping antiplatelet agents ≥3 months.
- Females with childbearing potential or breast-feeding.
- Co-administration of contraindicated medications as follows: anticoagulants (warfarin, direct oral anticoagulants (DOACs), or chronic therapy of heparin); cytochrome P450 2C19 inhibitors (fluoxetine, moclobemid or voriconazole); probenecid; high dose of methotrexate (≥15 mg/week); lithium.
- Inability to have a complete follow-up for up to 5 years from randomization (e.g: high possibility of travelling outside the country).
- Inability to afford paying for Clopidogrel out-of-pocket up to 5 years from randomization (in case not being covered by the health care system).
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Khalid F Alhabiblead
MeSH Terms
Interventions
Intervention Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Khalid Alhabib
King Saud University
Central Study Contacts
Study Design
- Study Type
- interventional
- Phase
- phase 3
- Allocation
- RANDOMIZED
- Masking
- NONE
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR INVESTIGATOR
- PI Title
- Professor of Cardiology
Study Record Dates
First Submitted
April 28, 2026
First Posted
May 7, 2026
Study Start (Estimated)
April 1, 2027
Primary Completion (Estimated)
April 1, 2032
Study Completion (Estimated)
April 1, 2032
Last Updated
May 7, 2026
Record last verified: 2026-05
Data Sharing
- IPD Sharing
- Will not share